Martin Reck - Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany;

基本信息

浏览量：375

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 603 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)

Solange Peters,Peter R Galle, Coen A Bernaards,Marcus Ballinger,René Bruno,Valerie Quarmby, Jane Ruppel, Alexandr Vilimovskij,Benjamin Wu, Nitzan Sternheim,Martin Reck

CTS-CLINICAL AND TRANSLATIONAL SCIENCE（2022）

引用0浏览0WOS引用

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami,Fabrice Barlesi,Mark A Socinski,Martin Reck,Christian A Thomas,Federico Cappuzzo,Tony S K Mok,Gene Finley,Joachim G Aerts,Francisco Orlandi,Denis Moro-Sibilot,Robert M Jotte,

Journal of Thoracic Oncology（2022）

引用76浏览0WOS引用

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

S Peters,J-L Pujol,U Dafni,M Dómine,S Popat,M Reck,J Andrade,A Becker,D Moro-Sibilot,A Curioni-Fontecedro,O Molinier,K Nackaerts,

Annals of Oncology（2022）

引用30浏览0WOS引用

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

M Reck,T-E Ciuleanu,M Cobo,M Schenker, B Zurawski, J Menezes,E Richardet,J Bennouna,E Felip,O Juan-Vidal, A Alexandru,H Sakai,

ESMO Open（2021）

引用78浏览0WOS引用

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Xiuning Le,Monique Nilsson,Jonathan Goldman,Martin Reck,Kazuhiko Nakagawa, Terafumi Kato,Luis Paz Ares,Bente Frimodt-Moller, Katharina Wolff,Carla Visseren-Grul,John V. Heymach,Edward B. Garon

Journal of Thoracic Oncology（2021）

引用100浏览0WOS引用

100

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

Rathi N Pillai,Suresh S Ramalingam,Meena Thayu, Patricia Lorenzini, Diana A Alvarez Arias,Christopher Moy, Natalie Hutnick,Roland Knoblauch,Huaibao Feng, Colleen Kane,Leora Horn,Martin Reck,

JTO Clinical and Research Reportsno. 2 (2021): 100104

引用0浏览0WOS引用

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

A J Schoenfeld,S J Antonia,M M Awad,E Felip,J Gainor,S N Gettinger,F S Hodi,M L Johnson,N B Leighl,C M Lovly,T Mok,M Perol,

Annals of Oncology（2021）

引用28浏览0WOS引用

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

M Kirchner, K Kluck, R Brandt,A-L Volckmar,R Penzel,D Kazdal,V Endris,O Neumann, H Seker-Cin, H Goldschmid, J Glade, M Allgäuer,

ESMO Open（2021）

引用12浏览0WOS引用

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

Aaron S Mansfield,Roy S Herbst,Gilberto de Castro,Rina Hui,Nir Peled,Dong-Wan Kim,Silvia Novello,Miyako Satouchi,Yi-Long Wu,Edward B Garon,Martin Reck,Andrew G Robinson,

JTO Clinical and Research Reportsno. 8 (2021): 100205

引用0浏览0WOS引用

Risk Assessment For Patients With Chronic Respiratory And Pulmonary Conditions In The Context Of The Sars-Cov-2 Pandemic Statement Of The German Respiratory Society (Dgp) With The Support Of The German Association Of Respiratory Physicians (Bdp)

M Lommatzsch,K F Rabe,C Taube, M Joest,M Kreuter,H Wirtz,T G Blum,M Kolditz, H Geerdes-Fenge,R Otto-Knapp, B Häcker,T Schaberg,

PNEUMOLOGIE（2021）

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn